Press Release
6.7.21

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

Zurich-Schlieren, Switzerland, July 6th, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today announced the completion of a Phase 1 dose escalation study of its lead compound, TOP-N53, a first-in-class wound healing drug candidate. The study was designed to allow for an increase to the next higher dose with six patients per dose level and a total of 30 healthy subjects were enrolled. As a result of the excellent safety profile of TOP-N53, the clinical study advanced through all five intended dose levels. The final results of this study will be reported once full datasets are available for pharmacokinetics, pharmacodynamics, and clinical observations for all enrolled subjects. "The absence of dose-limiting toxicity gives us great confidence that TOP-N53 will be safe for use in patients following longer-term administration," said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “I’m encouraged by the completion of this study as this is an essential first step into the clinical development of TOP-N53” commented Dr. Naef.

Download DocumentDokument herunterladen
19.5.22
Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

Read more
27.10.20
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
23.3.22
Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

Read more